Analyst Ratings For NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS)
Today, Cann reiterated its Hold rating on NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS).
Some recent analyst ratings include
- 6/11/2018-Cann Reiterated Rating of Hold.
- 2/22/2018-Evercore ISI Upgrade from a “In-Line ➝ Outperform” rating to a “” rating.
Recent Insider Trading Activity For NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS)
NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS) has insider ownership of 10.20% and institutional ownership of 94.01%.
- On 4/9/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.02 per share and the total transaction amounting to $270,090.00.
- On 3/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $61.47 per share and the total transaction amounting to $276,615.00.
- On 2/22/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $60.00 per share and the total transaction amounting to $270,000.00.
- On 2/15/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $54.09 per share and the total transaction amounting to $162,270.00.
- On 1/16/2018 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $59.16 per share and the total transaction amounting to $177,480.00.
- On 1/8/2018 Thorlef Spickschen, Director, sold 4,500 with an average share price of $64.97 per share and the total transaction amounting to $292,365.00.
- On 12/15/2017 Gillian C Ivers-Read, Insider, sold 3,000 with an average share price of $64.16 per share and the total transaction amounting to $192,480.00.
Recent Trading Activity for NASDAQ:CLVS – Clovis Oncology (NASDAQ:CLVS)
Shares of NASDAQ:CLVS – Clovis Oncology closed the previous trading session at 41.91 down -1.83 4.18% with shares trading hands.